Efficacy and Tolerance of URGO AWC_008 and URGO AWC_022 Dressings (EXPANSION)

Evaluation of the efficacy (wound epithelialization and time to closure) and tolerance (emergence and nature of adverse event) of the new URGO AWC_008 and URGO AWC_022 dressings in local management of acute and chronic wounds at risk of local infection or with clinical signs of local infection

prospective multicenter, non comparative clinical investigation

This is a prospective multicenter, non comparative open-label, clinical investigation conducted in patients with acute and chronic wounds at risk of local infection or with clinical signs of local infection.

This study is carried out in France and Spain in around 30 investigator sites. A total of 85 patients meeting the eligibility criteria will be included. The patients will be followed for 4 weeks and a total of 5 clinical evaluations will be carried out by the investigating centers.

A planimetric survey of the studied wounds is carried out during the initial assessment of the wound (Day 0) and at each assessment provided for in the protocol (Week 1, Week 2, Week 3 and Week 4).

Eligibility Criteria:
Inclusion Criteria :

Related to all wounds :

* Adult patient having given free, informed and written consent
* Patient affiliated to a social security insurance scheme (applicable For France),
* Inpatient or outpatient who can be followed by the same investigative team throughout the investigation,
* Acute wound (burn, traumatic wound, unstitched surgical wound) or chronic wound (leg ulcer, pressure ulcer, diabetic foot ulcer),
* Wound whose surface can be covered by a single dressing,
* Wound at least 3 cm from any edge of another wound.

Related to acute wounds, leg ulcer, pressure ulcer:

Patient whose studied wound presents a risk of local infection (based on modified W.A.R. score ≥ 3 points) or with at least 3 of the following clinical signs:

* Pain (spontaneous, pressure pain or increased pain),
* Peri-wound erythema,
* Oedema, induration or swelling,
* Odour (increase, change),
* Exudate (colour modification or increase of exudate),
* Local warmth,
* Hypergranulation,
* Bleeding, friable granulation tissue,
* Stagnant healing/wound deterioration.

Related to diabetic foot ulcer :

Patient whose studied wound presents a risk of local infection (based on modified W.A.R. score ≥ 3 points) or with at least 2 of the following clinical signs:

* Pain (spontaneous, pressure pain or increased pain),
* Peri-wound erythema between 0.5-2.0 cm around the wound,
* Oedema, induration or swelling,
* Odour (increase, change),
* Exudate (colour modification or increase of exudate),
* Local warmth,
* Hypergranulation,
* Bleeding, friable granulation tissue,
* Stagnant healing/wound deterioration,

Exclusion Criteria:

* Patient with a wound for which treatment in a hyperbaric chamber is planned within 4 weeks following inclusion,
* Patient with a serious general condition, that could lead to withdrawal from the trial before four weeks of treatment,
* Patient who has experienced an acute ischaemic event (acute myocardial infarction or stroke) during the 3 months prior to inclusion in the investigation,
* Patient with a systemic infection
* Wound totally or partially covered on its surface with a black plaque of necrosis,
* Cancerous wound